Resources Repository
-
ReviewPublication 2016Using Economic Evidence to Set Healthcare Priorities in LMIC
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks …
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks for identifying priority health interventions. This paper synthesizes and appraises the literature on methodological frameworks – which incorporate economic evaluation evidence – for the purpose of setting healthcare priorities in LMICs. A systematic search of Embase, MEDLINE, Econlit and PubMed identified 3968 articles with a further 21 articles identified through manual searching. A total of 36 papers were eligible for inclusion.…
Latin America & Caribbean | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
Resource PackPublication, Teaching Resource 2020Resource Pack: Cost-Effectiveness of SSB Excise Taxes
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior …
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior has been of increasing interest in the last decade as the evidence-base builds for the health and economic consequences of obesity, overweight, and unhealthy eating. The motivation for using fiscal instruments in nutrition policy is to make the unhealthy option less affordable and less economically attractive by increasing the price via a tax, and therefore reduce the incentive to consume…
Europe | Latin America & Caribbean | Health Outcomes | Evidence Synthesis | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Policy/Regulation | Business/Industry | Economics/Finance | Food/Agriculture | Government/Law | Health/Medicine | North America | Oceania -
ArticlePublication 2018DALYS and QALYs – Does the Choice of Measure Matter?
This article discusses the measurement of health benefits as a key issue in health economic …
This article discusses the measurement of health benefits as a key issue in health economic evaluations. Authors adapted two previously published models, a Markov model for human papilloma virus (HPV) vaccination, and a pneumococcal vaccination deterministic model (PNEUMO) that reported outputs in QALYs to estimate DALYs in 3 settings, Argentina, Chile, and the United Kingdom. While the authors found that QALY gains were larger than DALYs avoided in all countries for HPV, differences using QALYs…
Europe | Latin America & Caribbean | Cost-Effectiveness Analysis | Infectious Diseases | Policy/Regulation | Health/Medicine -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Europe | Preferences/Values | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Dynamic Transmission | Latin America & Caribbean | Health Outcomes | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Europe | Latin America & Caribbean | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Dynamic Transmission | Latin America & Caribbean | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Health Systems | Global Governance | Climate/Environment | Economics/Finance | Health/Medicine | Asia & Pacific -
BookPublication 2016Cost-Effectiveness in Health and Medicine, 2nd Edition
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The …
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The Second Panel on Cost-Effectiveness in Health and Medicine included experts drawn from academia, healthcare administration, and government. The book offers advice for conducting analyses to improve the allocation of health resources, and is intended for economists, policy analysts, hospital executives, and students across health, business, and humanities disciplines. New components of this edition, include an in-depth review of the past 20…
Europe | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Global | North America -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Europe | Preferences/Values | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Health/Medicine | Science/Technology | North America